Document hub

Our international presence

Return to Hikma.com
Contact Us

Popular searches

Operations

Decorative image.

Core to Hikma’s strategy is having a strong local presence in our markets.

We have an extensive network of manufacturing facilities across the US, MENA and Europe and are continually expanding this presence by building new sites and expanding existing ones. Through our local sites, we are uniquely positioned to respond quickly to evolving healthcare needs and priorities and to ensure greater reliability of supply.

Top 10 generic pharma company in the US

We have three large manufacturing facilities in New Jersey and Ohio supply generic injectable, non-injectable and specialty products across a broad range of therapeutic areas, including respiratory, oncology and pain management. We also have a facility supplying compounded injectable products. We have two R&D facilities to support sustainable growth.

Top 2 pharma company in MENA

We sell branded generics and in-licensed patented products across the MENA. We have 20 manufacturing plants in six countries, including US FDA-inspected plants in Jordan and Saudi Arabia. Around 2,000 sales representatives and support staff market our brands to healthcare professionals across 18 markets. We also manufacture certain APIs through our API manufacturing facility in Jordan. Our significant footprint enables us to deliver on our corporate strategy and promote access to medicine across the region.

Growing presence in Europe

In Europe, we have manufacturing sites in Portugal, Germany and Italy, which supply our global markets with sterile injectable products. These facilities have a range of capabilities, including dedicated capacity for oncology, cephalosporins and lyophilised products. We have an R&D facility in Croatia, and commercial presence in Austria, BENELUX, France, Germany, Italy, Portugal, Spain and the UK.

Sterile injectable Oncology Lyophilisation Medicines
Key stats
9,100 employees
30 manufacturing plants
9 R&D hubs
13 US FDA-inspected plants
12 EMA-inspected plants
Related content

Explore more

1. IQVIA MAT through November 2023, includes all generic injectable and non-injectables
2.  Branded. Based on internal analysis by Hikma using IQVIA MIDAS® Monthly value sales data for Kuwait, KSA, UAE, Jordan, Lebanon, Egypt, Tunisia, Algeria and Morocco, MAT Dec 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.